Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2019-10-30 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
2019年第三季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled "2019 年第三季度报告全文" which translates to "2019 Third Quarter Report Full Text." It contains detailed financial data including consolidated and parent company balance sheets, profit and loss statements, cash flow analysis, and explanations of financial changes during the quarter. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year (third quarter) clearly indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2019
2019-10-30 Chinese
独立董事对第四届董事会第一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion statement from the independent directors of 瑞康医药集团股份有限公司 regarding the first meeting of the fourth board of directors. It discusses the appointment of senior management and opinions on related party transactions. There are no financial statements or detailed financial data presented. The document is a formal opinion related to board/management matters rather than a full report or announcement of financial results. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on governance and management appointments, not an annual or interim report or regulatory filing.
2019-10-30 Chinese
2019年第三季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2019 Third Quarter Report" of 瑞康医药集团股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data such as assets, liabilities, income, cash flows, shareholder information, and management commentary on financial changes during the quarter. The length is 7,836 characters, which is sufficient to contain substantive financial data and analysis. The content includes financial statements and explanations typical of an interim or quarterly report. There is no indication that this is merely an announcement or a certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2019
2019-10-30 Chinese
关于“17瑞康01”投资者回售结果的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the results of an investor put-back (回售) of a specific bond "17瑞康01" issued by 瑞康医药集团股份有限公司. It details the number of bonds put back, the amount involved, and the payment schedule. There is no financial statement or comprehensive report content, only a notification of the outcome of a bondholder action. This fits the category of a Capital/Financing Update (CAP), as it relates to bond financing and investor redemption results.
2019-10-17 Chinese
2017年面向合格投资者公开发行公司债券（第一期）2019年付息公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the interest payment for a corporate bond issued by 瑞康医药集团股份有限公司 in 2017. It details the bond's basic information, interest payment schedule, tax implications, and contact information. The document does not contain financial statements or comprehensive financial analysis but serves as a formal notice to bondholders about the interest payment date and related procedures. It is not an annual report, interim report, earnings release, or any other detailed financial report. It is also not a regulatory filing or certification. Given the content and purpose, this document fits best under Capital/Financing Update (CAP), as it relates to bond issuance and interest payment updates.
2019-10-16 Chinese
2019年第五次临时股东大会决议的公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the resolutions passed at the 2019 fifth extraordinary general meeting of shareholders of 瑞康医药集团股份有限公司. It details the meeting date, attendance, voting results on various proposals including changes in company type, guarantees, investment projects, and election of board and supervisory candidates. The document is a formal disclosure of voting results from a shareholders' meeting, not a full report or presentation. It matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)' which covers official results from shareholder votes at any general meeting. The document length is about 5,347 characters, which is sufficient to include detailed voting results rather than just a brief announcement or a report publication notice. Therefore, the correct classification is DVA with high confidence.
2019-10-08 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.